Overview

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

Status:
Completed

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Orion Corporation, Orion Pharma

Treatments:

Carbidopa
Carbidopa, levodopa drug combination
Entacapone
Levodopa